Topical application of beneficial lactobacilli and potentially other ‘live biotherapeutic products’ (LBPs) show great potential as an alternative strategy to tackle skin care problems related to disturbance of the skin microbiome, providing alternatives to the […]
Crown Laboratories, Inc. (“Crown”), a leading, fully integrated skin care company, announced it has acquired Xycrobe Therapeutics, Inc. (“Xycrobe”). Xycrobe’s technology focuses on utilizing the ubiquitous nature of skin microbes by turning them into vehicles […]
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, […]
MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated […]
For over 25 years, Healthy Directions has been forging a path to better health with innovative products developed by leading health experts. Today, they announce the new LifeBiome™ product line, inspired by nature and uniquely […]
BioCompute, a collaboration between The George Washington University and the FDA to improve communication of bioinformatics pipelines, today announced a new guidance for life sciences companies using next generation sequencing (NGS) analysis as part of […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the […]
Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]
Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]